X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10243) 10243
Book Review (1850) 1850
Publication (536) 536
Book / eBook (57) 57
Newsletter (44) 44
Book Chapter (38) 38
Newspaper Article (28) 28
Conference Proceeding (19) 19
Magazine Article (12) 12
Dissertation (8) 8
Data Set (3) 3
Web Resource (2) 2
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9594) 9594
index medicus (9358) 9358
male (5565) 5565
female (5012) 5012
middle aged (4764) 4764
esophageal neoplasms - drug therapy (4677) 4677
aged (4303) 4303
esophageal cancer (3864) 3864
oncology (3851) 3851
esophageal neoplasms - pathology (3407) 3407
cancer (3241) 3241
adult (2709) 2709
surgery (2143) 2143
chemotherapy (2115) 2115
antineoplastic combined chemotherapy protocols - therapeutic use (2002) 2002
esophageal neoplasms - surgery (1910) 1910
carcinoma, squamous cell - drug therapy (1859) 1859
esophageal neoplasms - radiotherapy (1740) 1740
treatment outcome (1716) 1716
prognosis (1667) 1667
combined modality therapy (1615) 1615
esophageal neoplasms - therapy (1364) 1364
carcinoma, squamous cell - pathology (1355) 1355
aged, 80 and over (1331) 1331
gastroenterology & hepatology (1318) 1318
care and treatment (1305) 1305
esophageal neoplasms - mortality (1262) 1262
adenocarcinoma (1254) 1254
cisplatin - administration & dosage (1252) 1252
neoplasm staging (1173) 1173
squamous-cell carcinoma (1162) 1162
cell line, tumor (1161) 1161
adenocarcinoma - drug therapy (1160) 1160
fluorouracil - administration & dosage (1158) 1158
esophageal neoplasms - metabolism (1123) 1123
esophagus (1112) 1112
esophageal neoplasms - genetics (1086) 1086
carcinoma (1077) 1077
squamous cell carcinoma (1062) 1062
animals (1058) 1058
abridged index medicus (1036) 1036
radiotherapy (1032) 1032
retrospective studies (998) 998
esophageal squamous cell carcinoma (962) 962
analysis (938) 938
research (920) 920
survival rate (915) 915
adenocarcinoma - pathology (910) 910
medicine & public health (894) 894
tumors (872) 872
chemoradiotherapy (868) 868
stomach neoplasms - drug therapy (839) 839
antineoplastic agents - therapeutic use (838) 838
survival (832) 832
esophagectomy (813) 813
therapy (811) 811
expression (809) 809
health aspects (805) 805
carcinoma, squamous cell - radiotherapy (803) 803
cisplatin (798) 798
metastasis (797) 797
apoptosis (795) 795
risk factors (753) 753
carcinoma, squamous cell - surgery (746) 746
follow-up studies (731) 731
neoadjuvant therapy (709) 709
survival analysis (678) 678
carcinoma, squamous cell - mortality (643) 643
chemotherapy, adjuvant (640) 640
cancer therapies (607) 607
mice (587) 587
carcinoma, squamous cell - metabolism (585) 585
immunohistochemistry (582) 582
antineoplastic combined chemotherapy protocols - adverse effects (578) 578
carcinoma, squamous cell - genetics (563) 563
carcinoma, squamous cell - therapy (560) 560
esophageal neoplasms - diagnosis (545) 545
disease-free survival (538) 538
stomach neoplasms - pathology (535) 535
adenocarcinoma - surgery (531) 531
breast-cancer (518) 518
prospective studies (517) 517
lymphatic metastasis (505) 505
medical prognosis (501) 501
drug therapy (496) 496
development and progression (489) 489
patients (485) 485
gene expression regulation, neoplastic (464) 464
time factors (459) 459
gene expression (456) 456
genetic aspects (456) 456
radiotherapy dosage (452) 452
drug administration schedule (447) 447
diagnosis (438) 438
apoptosis - drug effects (435) 435
barretts-esophagus (435) 435
proteins (435) 435
trial (431) 431
mortality (424) 424
cell proliferation - drug effects (420) 420
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (40) 40
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Credit Valley Hospital - Stacks (2) 2
Online Resources - Online (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Mt Sinai Hospital - Pathology (1) 1
OISE - Stacks (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - General (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9212) 9212
Japanese (547) 547
French (161) 161
German (153) 153
Chinese (148) 148
Russian (75) 75
Spanish (37) 37
Italian (32) 32
Hungarian (10) 10
Polish (9) 9
Dutch (8) 8
Korean (6) 6
Danish (5) 5
Portuguese (4) 4
Swedish (4) 4
Hebrew (3) 3
Croatian (2) 2
Czech (2) 2
Lithuanian (2) 2
Romanian (2) 2
Afrikaans (1) 1
Bulgarian (1) 1
Norwegian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 06/2017, Volume 23, Issue 6, pp. 664 - 673
Neuroendocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and treated on the basis of their site of origin. This Perspective focuses on... 
MOLECULAR CHARACTERIZATION | MEDICINE, RESEARCH & EXPERIMENTAL | PANCREATIC ENDOCRINE NEOPLASMS | TRANSGENIC MOUSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIANDROGEN RESISTANCE | CONDITIONAL MOUSE MODEL | AURORA KINASE | METASTATIC PROSTATE-CANCER | T-ANTIGEN | CELL BIOLOGY | CELL LUNG-CANCER | N-MYC | Lung Neoplasms - drug therapy | Colonic Neoplasms - genetics | Carcinoma, Small Cell - genetics | Colonic Neoplasms - drug therapy | Epigenesis, Genetic | Humans | Male | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Tumor Suppressor Protein p53 - genetics | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Prostatic Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Female | Cell Differentiation | Retinoblastoma Binding Proteins - genetics | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Triazoles - therapeutic use | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Neuroendocrine - drug therapy | Carcinoma, Small Cell - drug therapy | Carcinogenesis - genetics | Head and Neck Neoplasms - drug therapy | Carcinoma, Neuroendocrine - genetics | Uterine Cervical Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Uterine Cervical Neoplasms - genetics | Disease Progression | Azepines - therapeutic use | Neuroendocrine Tumors - genetics | Proto-Oncogene Proteins c-met - genetics | Cell Lineage | Cell Plasticity - genetics | Esophageal Neoplasms - genetics | Pyrimidines - therapeutic use | Neuroendocrine Tumors - drug therapy | Head and Neck Neoplasms - genetics | Proto-Oncogene Proteins c-myc - genetics | Ubiquitin-Protein Ligases - genetics | Benzodiazepines - therapeutic use | Esophageal Neoplasms - drug therapy | Proteins | Research | Health aspects | Carcinogenesis | Gastrin | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1224 - 1235
Summary Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | ONCOLOGY | BEVACIZUMAB | CLINICAL-TRIALS | GROWTH | 2ND-LINE CHEMOTHERAPY | OPEN-LABEL | 1ST-LINE THERAPY | COMBINATION | CANCER | III TRIAL | Confidence Intervals | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Esophageal Neoplasms - mortality | Adult | Female | Remission Induction - methods | Paclitaxel - administration & dosage | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Paclitaxel - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Hospitals | Clinical trials | Monoclonal antibodies | Product development | Antineoplastic agents | Vascular endothelial growth factor | Esophageal cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2016, Volume 34, Issue 5, pp. 443 - 451
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 01/2018, Volume 110, Issue 1, pp. 109 - 120
Background: Cancer-associated fibroblasts (CAFs) are tumor-promoting and correlate with poor survival in many cancers, which has led to their emergence as... 
CELL LUNG-CANCER | PHASE-II TRIAL | OXIDATIVE STRESS | ONCOLOGY | NAB-PACLITAXEL | ACTIVATION PROTEIN | DEPENDENT INVASION | PANCREATIC-CANCER | MONOCLONAL-ANTIBODY | DIFFERENTIATION | STROMAL CELLS | Lung Neoplasms - drug therapy | Up-Regulation | Pyrazoles - therapeutic use | Reactive Oxygen Species - metabolism | Cell Count | Humans | Middle Aged | Male | Oropharyngeal Neoplasms - pathology | Head and Neck Neoplasms - chemistry | RNA Interference | Cancer-Associated Fibroblasts - chemistry | Aged, 80 and over | NADPH Oxidases - genetics | Adenocarcinoma - chemistry | Esophageal Neoplasms - chemistry | Lung Neoplasms - chemistry | NADPH Oxidases - antagonists & inhibitors | Head and Neck Neoplasms - drug therapy | Carcinoma, Squamous Cell - chemistry | Survival Rate | Adenocarcinoma - drug therapy | Disease Progression | Phenotype | Carcinoma, Squamous Cell - drug therapy | Head and Neck Neoplasms - genetics | Mice | Neoplasm Transplantation | Carcinoma, Non-Small-Cell Lung - chemistry | Carcinoma, Squamous Cell - genetics | Colorectal Neoplasms - chemistry | Cell Transdifferentiation - genetics | Myofibroblasts - chemistry | Actins - analysis | Cell Transdifferentiation - drug effects | Adult | Female | Adenocarcinoma - genetics | Cancer-Associated Fibroblasts - physiology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Myofibroblasts - pathology | Carcinoma, Non-Small-Cell Lung - genetics | NADPH Oxidases - analysis | Mouth Neoplasms - chemistry | NADPH Oxidase 4 | Cancer-Associated Fibroblasts - pathology | Animals | Esophageal Neoplasms - genetics | Mouth Neoplasms - pathology | Oropharyngeal Neoplasms - chemistry | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Colorectal Neoplasms - pathology | Esophageal Neoplasms - drug therapy | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1512 - 1522
Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy and combine the ability of monoclonal antibodies to specifically target tumour... 
HETEROGENEITY | EMTANSINE | THERAPY | ONCOLOGY | CANCER AMERICAN SOCIETY | CLINICAL-PRACTICE GUIDELINE | GENE AMPLIFICATION | JUNCTION CANCER | HER2 STATUS | OPEN-LABEL | PLUS PACLITAXEL | Breast Neoplasms - surgery | Prognosis | Receptor, ErbB-2 - genetics | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Mastectomy - methods | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Patient Safety | Esophageal Neoplasms - mortality | Immunoconjugates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Receptor, ErbB-2 - drug effects | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Drug Administration Schedule | Japan | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - genetics | Esophageal Neoplasms - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Antimitotic agents | Care and treatment | Safety and security measures | Monoclonal antibodies | Antineoplastic agents | Biopharmaceutics | Tumors | Enzymes | Medical research | Analysis | Medicine, Experimental | Health aspects | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1090 - 1098
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 481 - 489
Summary Background EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | CETUXIMAB | PROSPECTIVE MULTICENTER | ONCOLOGY | GASTRIC-CANCER | PROGNOSTIC-SIGNIFICANCE | CELL-LINES | METASTATIC COLORECTAL-CANCER | ESOPHAGEAL ADENOCARCINOMA | III TRIAL | Multivariate Analysis | Adenocarcinoma - pathology | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Molecular Targeted Therapy | Esophageal Neoplasms - pathology | Early Termination of Clinical Trials | Organoplatinum Compounds - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Fluorouracil - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Stomach Neoplasms - enzymology | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | United Kingdom | Stomach Neoplasms - drug therapy | Chi-Square Distribution | Adenocarcinoma - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Esophageal Neoplasms - enzymology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Care and treatment | Anthracyclines | Product development | Cancer | Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2010, Volume 102, Issue 1, pp. 220 - 226
BACKGROUND: Radiotherapy for breast cancer reduces disease recurrence and breast cancer mortality. However, it has also been associated with increased second... 
Risk | Breast cancer | Radiotherapy | Second primary neoplasms | Radiation | MORTALITY | QUALITY | LUNG-CARCINOMA | breast cancer | second primary neoplasms | RADIATION-THERAPY | WOMEN | IRRADIATION | CONTRALATERAL BREAST | ONCOLOGY | radiation | INCREASED RISK | radiotherapy | EXPOSURES | risk | SURVIVORS | Esophageal Neoplasms - etiology | Breast Neoplasms - surgery | United States - epidemiology | Soft Tissue Neoplasms - etiology | Follow-Up Studies | Humans | Middle Aged | Breast Neoplasms - etiology | Mastectomy - methods | National Cancer Institute (U.S.) | Bone Neoplasms - epidemiology | Antineoplastic Agents - therapeutic use | Radiotherapy - adverse effects | Esophageal Neoplasms - epidemiology | Lung Neoplasms - etiology | Registries - statistics & numerical data | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Mastectomy - statistics & numerical data | Soft Tissue Neoplasms - epidemiology | Breast Neoplasms - epidemiology | Pleural Neoplasms - epidemiology | Survivors | Combined Modality Therapy | Radiotherapy - statistics & numerical data | Breast Neoplasms - drug therapy | Bone Neoplasms - etiology | Pleural Neoplasms - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Breast Neoplasms - radiotherapy | Lung Neoplasms - epidemiology | Aged | Neoplasms, Radiation-Induced - epidemiology | Index Medicus | Epidemiology
Journal Article